A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control.

Trial Profile

A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Sitagliptin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 Jun 2015 Primary endpoint of Least Squares Mean Change From Baseline in HbA1c at Week 30 (for non-inferiority) has been met, according to results published in the Drugs and Aging.
    • 04 Jun 2015 Results published in the Drugs and Aging.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top